☆ 4.6 Article

Comparative analysis of adjuvant therapy for stage III BRAF-mut melanoma: A real-world retrospective study from single center in China

CANCER MEDICINE (2023)

相关参考文献

注意：仅列出部分参考文献，下载原文获取全部文献信息。

Article Oncology

Adjuvant Therapy of Nivolumab Combined With Ipilimumab Versus Nivolumab Alone in Patients With Resected Stage IIIB-D or Stage IV Melanoma (CheckMate 915)

Jeffrey S. Weber et al.

Summary: The CheckMate 915 trial compared adjuvant nivolumab plus ipilimumab with nivolumab alone in patients with resected melanoma. The study found that there was no significant difference in recurrence-free survival between the two treatment groups.

JOURNAL OF CLINICAL ONCOLOGY (2023)

添加到收藏夹

Article Dermatology

Benefit and toxicity of programmed death-1 blockade vary by ethnicity in patients with advanced melanoma: an international multicentre observational study

Xue Bai et al.

Summary: Based on the analysis of clinical data, white patients with unresectable or advanced melanoma treated with PD-1 monotherapy showed higher objective response rate and longer progression-free survival compared to East Asian, Hispanic, and African patients. However, in acral/mucosal/uveal melanomas, patients from different ethnic groups had similar treatment outcomes. White patients had higher rates of gastrointestinal irAEs, while other ethnic groups had higher rates of endocrine, liver, and other rare types of irAEs.

BRITISH JOURNAL OF DERMATOLOGY (2022)

添加到收藏夹

Article Oncology

Multicenter real-world data of adjuvant treatment and disease outcome of patients with melanoma with high-risk of recurrence.

Elisabeth Livingstone et al.

JOURNAL OF CLINICAL ONCOLOGY (2022)

添加到收藏夹

Review Medicine, Research & Experimental

Clinical features, molecular pathology, and immune microenvironmental characteristics of acral melanoma

Jianping Gui et al.

Summary: Acral melanoma is an aggressive subtype of melanoma that differs from other types in terms of its pathogenesis and immune microenvironment.

JOURNAL OF TRANSLATIONAL MEDICINE (2022)

添加到收藏夹

Article Oncology

Melanoma recurrence patterns and management after adjuvant targeted therapy: a multicentre analysis

Prachi Bhave et al.

Summary: The study found that patients who relapse after adjuvant TT respond well to subsequent anti-PD-1 therapy, with outcomes similar to those seen when first-line anti-PD-1 therapy is used in stage IV melanoma.

BRITISH JOURNAL OF CANCER (2021)

添加到收藏夹

Article Oncology

Adjuvant pembrolizumab versus placebo in resected stage III melanoma (EORTC 1325-MG/KEYNOTE-054): distant metastasis-free survival results from a double-blind, randomised, controlled, phase 3 trial

Alexander M. M. Eggermont et al.

Summary: The study demonstrated that adjuvant pembrolizumab therapy can improve the 3.5-year distant metastasis-free survival in patients with resected high-risk stage III cutaneous melanoma, with a more significant effect in patients with PD-L1-positive tumors.

LANCET ONCOLOGY (2021)

添加到收藏夹

Article Oncology

Overall Survival of Patients With Unresectable or Metastatic BRAF V600-Mutant Acral/Cutaneous Melanoma Administered Dabrafenib Plus Trametinib: Long-Term Follow-Up of a Multicenter, Single-Arm Phase IIa Trial

Lili Mao et al.

Summary: The combination treatment of dabrafenib and trametinib shows long-term survival benefits in Chinese patients with BRAF V600-mutant, unresectable or metastatic acral/cutaneous melanoma. The study found a high objective response rate and overall survival rate in these patients.

FRONTIERS IN ONCOLOGY (2021)

添加到收藏夹

Article Oncology

Management of early melanoma recurrence despite adjuvant anti-PD-1 antibody therapy

C. N. Owen et al.

ANNALS OF ONCOLOGY (2020)

添加到收藏夹

Article Oncology

Safety, Efficacy, and Biomarker Analysis of Toripalimab in Previously Treated Advanced Melanoma: Results of the POLARIS-01 Multicenter Phase II Trial

Bixia Tang et al.

CLINICAL CANCER RESEARCH (2020)

添加到收藏夹

Article Medicine, General & Internal

Adjuvant nivolumab plus ipilimumab or nivolumab monotherapy versus placebo in patients with resected stage IV melanoma with no evidence of disease (IMMUNED): a randomised, double-blind, placebo-controlled, phase 2 trial

Lisa Zimmer et al.

LANCET (2020)

添加到收藏夹

Article Oncology

Longer Follow-Up Confirms Recurrence-Free Survival Benefit of Adjuvant Pembrolizumab in High-Risk Stage III Melanoma: Updated Results From the EORTC 1325-MG/KEYNOTE-054 Trial

Alexander M. M. Eggermont et al.

JOURNAL OF CLINICAL ONCOLOGY (2020)

添加到收藏夹

Article Oncology

Adjuvant nivolumab versus ipilimumab in resected stage IIIB-C and stage IV melanoma (CheckMate 238): 4-year results from a multicentre, double-blind, randomised, controlled, phase 3 trial

Paolo A. Ascierto et al.

LANCET ONCOLOGY (2020)

添加到收藏夹

Article Medicine, General & Internal

Five-Year Analysis of Adjuvant Dabrafenib plus Trametinib in Stage III Melanoma

Reinhard Dummer et al.

NEW ENGLAND JOURNAL OF MEDICINE (2020)

添加到收藏夹

Article Medicine, General & Internal

Five-Year Outcomes with Dabrafenib plus Trametinib in Metastatic Melanoma

C. Robert et al.

NEW ENGLAND JOURNAL OF MEDICINE (2019)

添加到收藏夹

Article Oncology

A Phase Ib Study of Pembrolizumab as Second-Line Therapy for Chinese Patients With Advanced or Metastatic Melanoma (KEYNOTE-151)

Lu Si et al.

TRANSLATIONAL ONCOLOGY (2019)

添加到收藏夹

Article Dermatology

Adjuvant therapy with nivolumab versus ipilimumab after complete resection of stage III/IV melanoma: Japanese subgroup analysis from the phase 3 CheckMate 238 study

Kenji Yokota et al.

JOURNAL OF DERMATOLOGY (2019)

添加到收藏夹

Article Oncology

Targeted Genomic Profiling of Acral Melanoma

Iwei Yeh et al.

JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2019)

添加到收藏夹

Editorial Material Oncology

Melanoma Staging: American Joint Committee on Cancer (AJCC) 8th Edition and Beyond

Jeffrey E. Gershenwald et al.

ANNALS OF SURGICAL ONCOLOGY (2018)

添加到收藏夹

Article Oncology

Adjuvant vemurafenib in resected, BRAFV600 mutation-positive melanoma (BRIM8): a randomised, double-blind, placebo-controlled, multicentre, phase 3 trial

Michele Maio et al.

LANCET ONCOLOGY (2018)

添加到收藏夹

Article Multidisciplinary Sciences

Whole-genome landscapes of major melanoma subtypes

Nicholas K. Hayward et al.

NATURE (2017)

添加到收藏夹

Article Oncology

Tumor infiltrating lymphocytes in acral lentiginous melanoma: a study of a large cohort of cases from Latin America

C. A. Castaneda et al.

CLINICAL & TRANSLATIONAL ONCOLOGY (2017)

添加到收藏夹

Article Oncology

MAPK Pathway and TERT Promoter Gene Mutation Pattern and Its Prognostic Value in Melanoma Patients: A Retrospective Study of 2,793 Cases

Xue Bai et al.

CLINICAL CANCER RESEARCH (2017)

添加到收藏夹

Article Oncology

Cobimetinib combined with vemurafenib in advanced BRAFV600-mutant melanoma (coBRIM): updated efficacy results from a randomised, double-blind, phase 3 trial

Paolo A. Ascierto et al.

LANCET ONCOLOGY (2016)

添加到收藏夹

Article Oncology

Targeted Next Generation Sequencing Identifies Markers of Response to PD-1 Blockade

Douglas B. Johnson et al.

CANCER IMMUNOLOGY RESEARCH (2016)

添加到收藏夹

© Peeref 2019-2024. All rights reserved.